The Latest Cardiac and Vascular News
(GLOBE NEWSWIRE via COMTEX) —The Onyx ONE Clear Study Builds Upon Body of Clinical Evidence to Inform Individualized DAPT Duration Following Stent Procedures DUBLIN – September 10, 2018 – Medtronic plc (NYSE:MDT) today announced the start of the Onyx ONE Clear Study in the U.S. and Japan that will evaluate one-month […]
(GLOBE NEWSWIRE via COMTEX) –DUBLIN – September 4, 2018 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14, 2018, in New York City. Karen Parkhill, executive vice president and chief financial officer […]
DUBLIN and MUNICH – August 28, 2018 – Medtronic plc (NYSE:MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures. The study evaluated patients with symptomatic persistent atrial fibrillation (AF) […]
DUBLIN – August 9, 2018 – Medtronic plc (NYSE:MDT) today announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver lifesaving defibrillation and antitachycardia pacing therapy all in one system, […]
DUBLIN – July 31, 2018 – Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary arterial hypertension (PAH). Through a first-of-its-kind collaboration, the Medtronic SynchroMed(TM) II drug delivery system and cardiac catheter technologies were leveraged to […]
DUBLIN and BALTIMORE – July 25, 2018 – Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, will deliver public comment during the Centers for Medicare & Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting on July 25, which will assess whether scientific evidence supports requiring […]
DUBLIN – July 19, 2018 – Medtronic plc (NYSE: MDT) today announced first enrollments in a new clinical trial evaluating the ECG (electrocardiography) Belt Research System (ECG Belt) as a diagnostic tool for optimizing cardiac resynchronization therapy (CRT) for patients with heart failure. The first patient enrolled in the ECG Belt for […]
(GLOBE NEWSWIRE via COMTEX) –DUBLIN – July 12, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) labeling expansion for the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead to include stimulation of the bundle of His. It is the only pacing lead on the market […]
DUBLIN – July 11, 2018 – Medtronic plc (NYSE: MDT) has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD(TM) System, a left ventricular assist device (LVAD) for patients with advanced heart failure. The HVAD System is the smallest commercially available LVAD, and […]
NEW YORK CITY – June 5, 2018 – Medtronic plc (NYSE: MDT) today is presenting its strategic roadmap and outlining its long-range plan for creating shareholder value at the 2018 Medtronic Institutional Investor and Analyst Day in New York City. The company is unveiling its pipeline across multiple businesses, asserting its […]
